PTGX

Protagonist Therapeutics, Inc

148.18

USD

+3.02

+2.08%

Sep 11, 15:59 UTC -4

Closed

Pre-Market

144.38

-3.80

-2.57%

Protagonist Therapeutics, Inc Profile

About

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.

Info & Links

CEO

Dinesh V. Patel

Headquarters

7707 GATEWAY BLVD., SUITE 140
NEWARK, CA 94560, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

132

Protagonist Therapeutics, Inc Statistics

Valuation Measures

Market Capitalization²

9.34B

Enterprise Value

8.92B

Enterprise Value/EBITDA(ttm)

158.25

Price to Earnings Ratio(ttm)

143.86

Price to Sales(ttm)

34.00

Price to Book(mrq)

11.32

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

29.40%

Profit Margin(ttm)

-337.17%

Return on Equity(ttm)

12.03%

Return on Invested Capital(ttm)

6.61%

Return on Assets(ttm)

11.23%

Income Statement

Revenue(ttm)

281.99M

Revenue Per Share(ttm)

4.36

Gross Profit(ttm)

281.99M

EBITDA(ttm)³

56.38M

Net Income Available to Common(ttm)

82.91M

Diluted EPS(ttm)

1.03

Share Statistics

Beta (5Y Monthly)

1.80

52-Week Change

151.75%

S&P 500 52-Week Change

18.73%

S&P 500 Member

Stock Optionable

Yes

Total Shares Outstanding¹

64.71M

Dividend Yield

0.00%

Float⁴

61.35M

% Held by Insiders

5.19%

% Held by Institutions

98.63%

Balance Sheet

Total Cash(mrq)

782.58M

Total Cash Per Share(mrq)

12.09

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

21.71%

Quick Ratio(mrq)

21.71%

Book Value Per Share(mrq)

13.01

Cash Flow

Operating Cash Flow Per Share(ytd)

2.40

Free Cash Flow(ytd)

169.73M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.